# Patient-Trial Match Report

*Generated: 2026-01-05 07:01:23*

## Patient Profile

- **Age**: 59
- **Sex**: Female
- **Cancer Type**: renal cell carcinoma

**Clinical Description**:
> 59-year-old female with metastatic clear cell renal cell carcinoma, status post nephrectomy (2022). First-line ipilimumab/nivolumab x4 induction then nivolumab maintenance - initial PR but progressed at 14 months. Second-line cabozantinib with mixed response, discontinued for grade 3 hand-foot syndrome and fatigue. Switched to lenvatinib/everolimus - progression at 6 months with new pulmonary and hepatic metastases. IMDC intermediate risk. Seeking novel approaches beyond standard IO/TKI combinations. HIF-2Î± inhibitors of interest. Labs show mild hyperbilirubinemia (1.4), otherwise WNL.

- **Location Preference**: United States

## Search Summary

- **Search terms used**: 3
- **Total trials evaluated**: 70
- **Excluded by fast filter**: 30
- **LLM scored**: 40

## ðŸŸ¢ HIGH Likelihood (7 trials)

### [NCT04974671](https://clinicaltrials.gov/study/NCT04974671)

**Phase II Trial Of Stereotactic Body Radiation Therapy (SBRT) for Oligoprogression on Immune Checkpoint Inhibitors (ICI) in Metastatic Renal Cell Carcinoma**

- **Sponsor**: Yale University
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has histologically confirmed renal cell carcinoma with metastatic disease.
- Patient has an ECOG status of 1, which is acceptable.
- Patient has received prior systemic therapy with an ICI regimen (ipilimumab/nivolumab) within the required timeframe.
- Patient has no brain metastases.

**? Uncertainties:**
- Lab values for organ function (absolute neutrophil count, serum creatinine, total bilirubin) are not provided.

**Assessment:**
> The patient's cancer type matches the trial's focus on metastatic renal cell carcinoma. She has prior treatment with immune checkpoint inhibitors and has an acceptable ECOG performance status. The main uncertainty lies in the missing lab values for organ function, although they are crucial for final eligibility.

---

### [NCT05327686](https://clinicaltrials.gov/study/NCT05327686)

**Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)**

- **Sponsor**: NRG Oncology
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Pathologically proven diagnosis of renal cell carcinoma prior to registration
- IMDC intermediate risk
- ECOG status of 1
- No brain metastases
- Age 59

**? Uncertainties:**
-  Hemoglobin level within 45 days prior to registration
- Platelet count within 45 days prior to registration
- Absolute neutrophil count (ANC) within 45 days prior to registration
- Calculated creatinine clearance within 45 days prior to registration
- Aspartate aminotransferase and alanine aminotransferase (AST and ALT) levels within 45 days prior to registration

**Assessment:**
> The patient's cancer type matches the trial's focus on metastatic renal cell carcinoma. The patient has been treated previously, which aligns with the trial's acceptance of previously treated patients. There are some uncertainties regarding specific lab values and counts, but overall, the other eligibility criteria appear to be met.

---

### [NCT05665361](https://clinicaltrials.gov/study/NCT05665361)

**A Phase I/II Study of Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC)**

- **Sponsor**: National Cancer Institute (NCI)
- **Phase**: Phase 1/Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has advanced clear cell renal cell carcinoma (ccRCC)
- Patient is aged 59, which is >= 18 years
- Patient's ECOG performance status is 1
- Patient has received checkpoint inhibitor therapy (ipilimumab, nivolumab)
- Patient has received or been ineligible for a VEGF pathway antagonist (cabozantinib, lenvatinib)
- Patient has at least one measurable lesion as she has progressive disease

**? Uncertainties:**
- No specific lab values for hematologic function and hepatic function are provided to verify eligibility criteria.

**Assessment:**
> The patient has a matching disease type (advanced clear cell renal cell carcinoma). She meets the age and ECOG performance status criteria. She has received the required prior therapies (checkpoint inhibitors and VEGF pathway antagonists) and presents with measurable disease. However, the lack of specific lab values for hematologic and hepatic function creates a minor uncertainty, but overall this aligns with the trial eligibility.

---

### [NCT04989959](https://clinicaltrials.gov/study/NCT04989959)

**An Exploratory Study of [18F]PT2385 PET/CT in Patients With Renal Cell Carcinoma**

- **Sponsor**: Orhan Kemal Oz
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 59
- Sex: female
- Cancer type: renal cell carcinoma (metastatic clear cell renal cell carcinoma)
- ECOG status: 1
- Co-mutations: VHL loss
- Country: United States

**? Uncertainties:**
- Labs show mild hyperbilirubinemia (1.4), otherwise WNL - need clarification on liver function criteria

**Assessment:**
> The patient's cancer type matches the trial's focus on clear cell renal cell carcinoma. The patient has prior therapies but the trial includes previously treated patients with metastatic disease. The key eligibility criteria related to liver dysfunction is uncertain due to lab values, but she is otherwise a strong candidate.

---

### [NCT05433142](https://clinicaltrials.gov/study/NCT05433142)

**A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb819 in Subjects With Relapsed or Refractory Clear Cell Renal Cell Carcinoma**

- **Sponsor**: Xencor, Inc.
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Measurable disease based on RECIST criteria
- ECOG performance status of 1
- Relapsed and refractory ccRCC with evidence of disease progression on standard-of-care therapies

**? Uncertainties:**
- Adequate tumor sample availability
- Labs showing mild hyperbilirubinemia may need verification on organ function

**Assessment:**
> The patient's cancer type, renal cell carcinoma, aligns with the trial's focus on clear cell renal cell carcinoma. She is also classified as relapsed and refractory, meeting the treatment line criteria. The ECOG status is acceptable. However, there are uncertainties around the availability of adequate tumor samples and organ function due to mild hyperbilirubinemia.

---

### [NCT06265285](https://clinicaltrials.gov/study/NCT06265285)

**Pilot Single-Arm, Pragmatic Trial of In-Home Versus In-Clinic Subcutaneous Nivolumab Administration Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program**

- **Sponsor**: Mayo Clinic
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Age: 59 (â‰¥ 18 years)
- ECOG status: 1
- Cancer type: renal cell carcinoma matches trial conditions
- Prior therapies include anti-angiogenic therapy; patient received cabozantinib
- Mild hyperbilirubinemia (1.4) is acceptable (< 1.5 x ULN)
- IMDC intermediate risk is aligned with eligibility for treatment
- Patient is located in the United States and meets geographic residency requirement (â‰¤ 35 miles)

**? Uncertainties:**
- Organ function labs (AST, ALT, ANC, platelet count, hemoglobin, serum creatinine) were not explicitly provided
- Residence has Wi-Fi availability is not verified
- Some inclusion criteria regarding willingness to comply with study protocol and completion of questionnaires are not explicitly confirmed

**Assessment:**
> The patient's cancer type matches the trial, and she has a relevant treatment history that meets eligibility for previously treated patients. ECOG status and age requirements are fulfilled. There are some uncertainties regarding lab results, but overall, the patient is a likely participant.

---

### [NCT06582017](https://clinicaltrials.gov/study/NCT06582017)

**A First-in-human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients With Locally Advanced Un-resectable and/or Metastatic Solid Tumors and Multiple Myeloma**

- **Sponsor**: Nammi Therapeutics Inc
- **Phase**: Phase 1
- **Status**: Recruiting
- **Confidence**: 85%

**âœ“ Supporting Factors:**
- Patient has histopathologically confirmed advanced metastatic renal cell carcinoma.
- Patient has an ECOG status of 1.
- Patient is 59 years old, which meets the age requirement of being at least 18 years old.
- Patient has progressed on standard therapies, which aligns with the trial requirement for patients who have progressed despite treatment.

**? Uncertainties:**
- Patient's organ function is not explicitly detailed in terms of laboratory results (other than mild hyperbilirubinemia).

**Assessment:**
> The patient's disease type is renal cell carcinoma, which matches the trial conditions. Additionally, the patient has progressed through multiple therapies, meeting trial inclusion criteria for previously treated patients. The ECOG status is acceptable, and the age requirement is met. However, there is a mild uncertainty regarding the comprehensive organ function status since detailed lab results are not provided.

---

## ðŸŸ¡ MEDIUM Likelihood (2 trials)

### [NCT00001238](https://clinicaltrials.gov/study/NCT00001238)

**Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders**

- **Sponsor**: National Cancer Institute (NCI)
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 65%

**âœ“ Supporting Factors:**
- Patient has renal cell carcinoma, which is being studied in the trial.
- Patient is over 2 years of age.
- Patient has VHL loss, which could indicate a genetic basis for her disease.

**âœ— Potential Conflicts:**
- Patient has previously been treated with multiple therapies, including ipilimumab, nivolumab, cabozantinib, lenvatinib, and everolimus. It is unclear if the trial excludes prior treatments or is for previously treated patients.

**? Uncertainties:**
- The trial eligibility criteria do not specify exclusions based on prior treatments, but a lack of clear inclusion of previously treated patients leaves some uncertainty.

**Assessment:**
> The patient's diagnosis of renal cell carcinoma aligns with the trial focus, and they have a relevant genetic mutation (VHL loss). However, the lack of clarity regarding the treatment line requirements leads to some uncertainty in eligibility.

---

### [NCT05059444](https://clinicaltrials.gov/study/NCT05059444)

**ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation**

- **Sponsor**: Guardant Health, Inc.
- **Phase**: N/A
- **Status**: Recruiting
- **Confidence**: 65%

**âœ“ Supporting Factors:**
- Age: 59 is above 18 years old
- Cancer type: renal cell carcinoma is included in the conditions studied
- ECOG status: 1 is acceptable
- No brain metastases reported

**âœ— Potential Conflicts:**
- Patient does not meet the requirement for initial treatment given with curative intent as the patient has a metastatic disease and has progressed through multiple lines of therapy.

**? Uncertainties:**
- Need more information on whether the patient is willing to undergo regular follow-up and monitoring as per standard of care
- Need clarification on patient's willingness to provide blood samples as outlined in the study protocol

**Assessment:**
> The patient's renal cell carcinoma diagnosis matches the trial condition. However, the patient has not had initial treatment with curative intent and has significant prior therapies, which raises doubts about eligibility. This leads to a medium confidence rating.

---

## ðŸŸ  LOW Likelihood (1 trials)

### [NCT05830058](https://clinicaltrials.gov/study/NCT05830058)

**Phase II Randomized Controlled Trial of Biologically Guided Stereotactic Body Radiation Therapy in Oligoprogressive Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma**

- **Sponsor**: City of Hope Medical Center
- **Phase**: Phase 2
- **Status**: Recruiting
- **Confidence**: 25%

**âœ“ Supporting Factors:**
- Patient has renal cell carcinoma, which is studied in the trial
- Patient has ECOG status of 1, which is acceptable for the trial

**âœ— Potential Conflicts:**
- Patient has prior systemic therapies beyond the 3 months requirement with checkpoint inhibitors, while the trial likely targets patients with oligoprogressive disease after systemic therapy
- Patient has documented disease progression at various treatment lines but the trial specifically looks for 1-5 sites of oligoprogression; historical treatments may classify the patient's situation as unsuitable

**Assessment:**
> The patient's cancer type aligns with the trial's focus, but the substantial history of systemic therapies, specifically beyond the established treatment pathways for oligoprogression, raises significant concerns regarding eligibility.

---

## Excluded (60 trials)

### Excluded by Fast Filter

| NCT ID | Reason |
|--------|--------|
| [NCT04723810](https://clinicaltrials.gov/study/NCT04723810) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05267626](https://clinicaltrials.gov/study/NCT05267626) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05584670](https://clinicaltrials.gov/study/NCT05584670) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06161532](https://clinicaltrials.gov/study/NCT06161532) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06401330](https://clinicaltrials.gov/study/NCT06401330) | Patient age 59 is above maximum age 30 |
| [NCT06571708](https://clinicaltrials.gov/study/NCT06571708) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT06660654](https://clinicaltrials.gov/study/NCT06660654) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT00026884](https://clinicaltrials.gov/study/NCT00026884) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT00033137](https://clinicaltrials.gov/study/NCT00033137) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT00050752](https://clinicaltrials.gov/study/NCT00050752) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT00646022](https://clinicaltrials.gov/study/NCT00646022) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT02012699](https://clinicaltrials.gov/study/NCT02012699) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT02402244](https://clinicaltrials.gov/study/NCT02402244) | Patient age 59 is above maximum age 25 |
| [NCT04606446](https://clinicaltrials.gov/study/NCT04606446) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04777994](https://clinicaltrials.gov/study/NCT04777994) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT04969835](https://clinicaltrials.gov/study/NCT04969835) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05225428](https://clinicaltrials.gov/study/NCT05225428) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05277051](https://clinicaltrials.gov/study/NCT05277051) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05297734](https://clinicaltrials.gov/study/NCT05297734) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| [NCT05520099](https://clinicaltrials.gov/study/NCT05520099) | Low relevance score (0.00) - trial doesn't appear to target patient's condition/biomarkers |
| ... | *and 10 more* |

### Excluded by Eligibility Assessment

| NCT ID | Sponsor | Reason |
|--------|---------|--------|
| [NCT05487859](https://clinicaltrials.gov/study/NCT05487859) | University of Alabam | Patient has received prior systemic therapy for advanced RCC within the past 3 weeks, conflicting with the trial requirement of no prior systemic therapy in the past 3 weeks. |
| [NCT05048212](https://clinicaltrials.gov/study/NCT05048212) | M.D. Anderson Cancer | Patient has renal cell carcinoma but trial specifically studies patients with untreated brain metastases. The patient has no brain metastases. |
| [NCT05361720](https://clinicaltrials.gov/study/NCT05361720) | Vanderbilt-Ingram Ca | Patient has prior systemic therapies for RCC (ipilimumab, nivolumab, cabozantinib, lenvatinib, everolimus), while trial excludes prior systemic therapy. |
| [NCT05931393](https://clinicaltrials.gov/study/NCT05931393) | University of Texas  | Patient has progressed on cabozantinib, but the trial requires cabozantinib sensitive disease of at least 6 months treatment. Patient only received cabozantinib for a mixed response and had to discontinue due to toxicity. |
| [NCT06004336](https://clinicaltrials.gov/study/NCT06004336) | M.D. Anderson Cancer | Patient has prior systemic therapy, which includes ipilimumab, nivolumab, cabozantinib, lenvatinib, everolimus, and trial is studying oligometastatic RCC without requirements for prior treatment. |
| [NCT06222593](https://clinicaltrials.gov/study/NCT06222593) | State University of  | Patient has been previously treated with multiple therapies including cabozantinib, while the trial is for patients who have experienced disease progression after RTK inhibitors. |
| [NCT06432036](https://clinicaltrials.gov/study/NCT06432036) | Jonsson Comprehensiv | Patient has metastatic renal cell carcinoma (RCC) which is not early stage (T1 or T2a, N0M0) as required by the trial. |
| [NCT06447103](https://clinicaltrials.gov/study/NCT06447103) | Jonsson Comprehensiv | Patient has undergone prior systemic therapy for kidney cancer (multiple treatments including ipilimumab, nivolumab, cabozantinib, lenvatinib, and everolimus), while the trial does not specify any allowance for previously treated patients. |
| [NCT07223541](https://clinicaltrials.gov/study/NCT07223541) | University of Oklaho | Patient has prior systemic therapies which conflicts with the trial inclusion of previously treated patients. |
| [NCT06699602](https://clinicaltrials.gov/study/NCT06699602) | Memorial Sloan Kette | Patient has prior systemic therapy for renal cell carcinoma, which is excluded by trial criteria. |
| [NCT07077083](https://clinicaltrials.gov/study/NCT07077083) | Massachusetts Genera | Patient has renal cell carcinoma, but does not have suspicious findings for post-ablation residual or recurrent ccRCC documented within 90 days prior to PET scan, which is required for inclusion. |
| [NCT07043608](https://clinicaltrials.gov/study/NCT07043608) | Kelly Fitzgerald, MD | Patient has renal cell carcinoma, but the trial specifies that participants must have bone metastases, which the patient profile does not confirm. |
| [NCT03291028](https://clinicaltrials.gov/study/NCT03291028) | Fox Chase Cancer Cen | Patient has progressed from prior systemic therapy, while the trial calls for patients who achieved clinical benefit from ICB and developed new/progressive lesions. |
| [NCT05700461](https://clinicaltrials.gov/study/NCT05700461) | Wenxin Xu | Patient has received multiple prior therapies, contradicting potential eligibility if the trial requires treatment-naive patients. |
| [NCT06093568](https://clinicaltrials.gov/study/NCT06093568) | Power Life Sciences  | Patient has prior systemic therapies which do not match the requirement for treatment-naive patients |
| [NCT07049926](https://clinicaltrials.gov/study/NCT07049926) | Merck Sharp & Dohme  | Patient has received multiple prior systemic therapies (ipilimumab, nivolumab, cabozantinib, lenvatinib, everolimus) but trial requires no other prior systemic therapy except adjuvant PD-(L)1 therapy. |
| [NCT07226544](https://clinicaltrials.gov/study/NCT07226544) | City of Hope Medical | Patient has prior systemic anti-tumor treatment for RCC which excludes eligibility for this trial that requires treatment-naive patients |
| [NCT04693377](https://clinicaltrials.gov/study/NCT04693377) | M.D. Anderson Cancer | This trial is studying patients with painful bone metastases, and there is no mention of the patient suffering from pain at an intensity of at least 4/10 from the target lesion. |
| [NCT06453642](https://clinicaltrials.gov/study/NCT06453642) | Fluidx Medical Techn | Patient has prior systemic therapy (ipilimumab, nivolumab, cabozantinib, lenvatinib, everolimus) while trial does not specify treatment for previously treated patients. |
| [NCT07293351](https://clinicaltrials.gov/study/NCT07293351) | Bristol-Myers Squibb | Patient has received prior therapies including ipilimumab and cabozantinib, which conflicts with the inclusion criteria stipulating no prior systemic therapy targeting CTLA-4 (ipilimumab) or cabozantinib. |
| ... | ... | *and 10 more* |

## Search Terms Used

| Term | Source | Confidence |
|------|--------|------------|
| renal cell carcinoma | manual | 1.0 |
| RCC | llm | 0.8 |
| clear cell renal cell carcinoma | llm | 0.8 |

## Information That Would Improve Matches

The following patient data was not provided but would help refine eligibility assessment:

- **Organ function labs** (hematology, liver, renal) - required by all interventional trials
